Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
25
2
2020
medline:
22
10
2020
entrez:
25
2
2020
Statut:
ppublish
Résumé
During the 2019 International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented the current status and made recommendations on the diagnostic use of molecular pathology, incorporating a premeeting survey. Bladder cancers are biologically diverse and can be separated into "molecular subtypes," based on expression profiling. These subtypes associate with clinical behavior, histology, and molecular alterations, though their clinical utility has not been demonstrated at present and use in bladder cancer is not recommended. Mutations in the TERT promoter are present in the majority of bladder cancers, including the noninvasive stage of tumor evolution, but not in reactive conditions. Mutational analysis of the TERT promoter thus distinguishes histologically deceptive cancers from their benign mimics in some cases. A minority of pathologists employ this test. FGFR3 mutations are common in bladder cancer, and metastatic urothelial carcinoma (UC) with such mutations frequently responds to erdafitinib, an FGFR inhibitor. Testing for FGFR3 alterations is required before using this drug. Metastatic UC responds to immune-oncology (IO) agents in 20% of cases. These are approved as first and second-line treatments in metastatic UC. Several biological parameters associate with response to IO agents, including tumor mutational burden, molecular subtype, and infiltration by programmed death-ligand 1-positive lymphocytes, detected by immunohistochemistry. Programmed death-ligand 1 immunohistochemistry is mandatory before administering IO agents in the first-line setting. In conclusion, much has been learned about the biology of bladder cancer, and this understanding has improved the care of patients with the disease.
Identifiants
pubmed: 32091435
doi: 10.1097/PAS.0000000000001453
pii: 00000478-202007000-00002
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30-e46Références
International Agency for Research on Cancer (IARC). GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2012. Available at: http://globocan.iarc.fr. Accessed December 12, 2019.
Moch H, Humphrey P, Ulbright T, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC; 2016.
National Comprehensive Cancer Network (NCCN). Bladder cancer. NCCN Clinical Guidelines in Oncology. Version 1.2020; 2019.
Warrick JI. Clinical significance of histologic variants of bladder cancer. J Natl Compr Canc Netw. 2017;15:1268–1274.
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165.
Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014;111:3110–3115.
Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540.e25–556.e25.
Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377–3386.
Marzouka NA, Eriksson P, Rovira C, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8:3737.
Sjodahl G, Eriksson P, Liedberg F, et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242:113–125.
Kamoun A, de Reynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2019. [Epub ahead of print].
Kardos J, Chai S, Mose LE, et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight. 2016;1:e85902.
Seiler R, Gibb EA, Wang NQ, et al. Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin Cancer Res. 2019;25:5082–5093.
Guo CC, Dadhania V, Zhang L, et al. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur Urol. 2016;70:611–620.
Warrick JI, Sjodahl G, Kaag M, et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol. 2019;75:18–22.
Warrick JI, Kaag M, Raman JD, et al. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma. Virchows Arch. 2017;471:337–345.
Guo CC, Majewski T, Zhang L, et al. Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer. Cell Rep. 2019;27:1781.e4–1793.e4.
Patschan O, Sjodahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol. 2015;68:824–832; discussion 835–836.
Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72:544–554.
Hovelson DH, Udager AM, McDaniel AS, et al. Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications. Eur Urol. 2018;74:741–753.
Sjodahl G, Eriksson P, Lovgren K, et al. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. Mod Pathol. 2018;31:1869–1881.
Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955–1959.
Amin MB, Eble JN. Urological Pathology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
Rebouissou S, Herault A, Letouze E, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol. 2012;227:315–324.
Downes MR, Weening B, van Rhijn BW, et al. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway. Histopathology. 2017;70:281–289.
Barth I, Schneider U, Grimm T, et al. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch. 2018;472:749–758.
Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004;64:4040–4048.
Palmeira C, Lameiras C, Amaro T, et al. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa. Urol Oncol. 2011;29:205–211.
Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27–42.
Fristrup N, Birkenkamp-Demtroder K, Reinert T, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 2013;182:339–349.
Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol. 2004;122:444–452.
Zaleski M, Gogoj A, Walter V, et al. Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system. Hum Pathol. 2019;84:275–282.
Shim JW, Cho KS, Choi YD, et al. Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch. 2008;452:353–362.
Hurst CD, Alder O, Platt FM, et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell. 2017;32:701.e7–715.e7.
Giedl J, Rogler A, Wild A, et al. TERT core promotor mutations in early-onset bladder cancer. J Cancer. 2016;7:915–920.
Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013;73:7162–7167.
Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013;110:17426–17431.
Rodriguez Pena MDC, Tregnago AC, Eich ML, et al. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch. 2017;471:761–767.
Wang CC, Huang CY, Jhuang YL, et al. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential. Histopathology. 2018;72:795–803.
Wang X, Lopez-Beltran A, Osunkoya AO, et al. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncol. 2017;13:705–714.
Isharwal S, Hu W, Sarungbam J, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol. 2019;248:260–265.
Kurtis B, Zhuge J, Ojaimi C, et al. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Ann Diagn Pathol. 2016;21:7–11.
Cheng L, Davidson DD, Wang M, et al. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology. 2016;69:107–113.
Akgul M, MacLennan GT, Cheng L. Distinct Mutational Landscape of inverted urothelial papilloma. J Pathol. 2019;249:3–5.
Cowan M, Springer S, Nguyen D, et al. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Mod Pathol. 2016;29:511–515.
Vail E, Zheng X, Zhou M, et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Ann Diagn Pathol. 2015;19:301–305.
Palsgrove DN, Taheri D, Springer SU, et al. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol. 2019;85:1–9.
Nguyen D, Taheri D, Springer S, et al. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch. 2016;469:427–434.
Thiem S, Herold T, Krafft U, et al. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. Pathol Int. 2017;67:597–601.
Zhong M, Tian W, Zhuge J, et al. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol. 2015;39:127–131.
Amin MB, Trpkov K, Lopez-Beltran A, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38:e20–e34.
Stoehr R, Taubert H, Zinnall U, et al. Frequency of TERT promoter mutations in prostate cancer. Pathobiology. 2015;82:53–57.
Zheng X, Zhuge J, Bezerra SM, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014;7:47.
Priemer DS, Wang M, Zhang S, et al. Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common clonality between small-cell carcinoma of the urinary bladder and urothelial carcinoma. Eur Urol Focus. 2018;4:880–888.
Epstein JI, Egevad L, Humphrey PA, et al. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38:e6–e19.
Brown NA, Lew M, Weigelin HC, et al. Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. Histopathology. 2018;72:354–356.
Al-Ahmadie HA, Iyer G, Janakiraman M, et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol. 2011;224:270–279.
United States Food and Drug Administration (FDA). Prescribing information for erdafitinib. 2019. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. Accessed February 11, 2020.
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–348.
Pietzak EJ, Bagrodia A, Cha EK, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. 2017;72:952–959.
van Oers JM, Wild PJ, Burger M, et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol. 2007;52:760–768.
van Rhijn BW, Catto JW, Goebell PJ, et al. Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urol Oncol. 2014;32:1078–1087.
van Rhijn BW, Musquera M, Liu L, et al. Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Mod Pathol. 2015;28:695–705.
van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912–1921.
van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58:433–441.
van Kessel KEM, van der Keur KA, Dyrskjot L, et al. Molecular markers increase precision of the european association of urology non-muscle-invasive bladder cancer progression risk groups. Clin Cancer Res. 2018;24:1586–1593.
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–150.
Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019;24:563–569.
Ning YM, Maher VE, Beaver JA, et al. Accelerating early access to immunotherapies for advanced urothelial carcinoma. Oncologist. 2018;23:139–142.
Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–1492.
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.
Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51–64.
Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757.
Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3:e172411.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–322.
Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–548.
Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35:2117–2124.
United States Food and Drug Administration (FDA). Pembrolizumab prescribing information. 2019. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s046lbl.pdf. Accessed February 11, 2020.
United States Food and Drug Administration (FDA). Pembrolizumab safety and effectiveness data. 2017. Available at: www.accessdata.fda.gov/cdrh_docs/pdf15/P150013S011B.pdf. Accessed February 11, 2020.
United States Food and Drug Administration (FDA). Atezolizumab prescribing information. 2019. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s012lbl.pdf. Accessed February 11, 2020.
United States Food and Drug Administration (FDA). PDL1 companion diagnostic for pembrolizumab. 2019. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013s011. Accessed May 10, 2019.
Rijnders M, van der Veldt AAM, Zuiverloon TCM, et al. PD-L1 antibody comparison in urothelial carcinoma. Eur Urol. 2019;75:538–540.
Hodgson A, Slodkowska E, Jungbluth A, et al. PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol. 2018;42:1059–1066.
United States Food and Drug Administration (FDA). PDL1 companion diagnostic for atezolizumab. 2019. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160002s006. Accessed May 10, 2019.
United States Food and Drug Administration (FDA). PD-L1 IHC 22C3 pharmDx. 2015. Available at: www.accessdata.fda.gov/cdrh_docs/pdf15/P150013c.pdf. Accessed February 11, 2020.
United States Food and Drug Administration (FDA). Ventana PD-L1(SP142) assay. 2016. Available at: www.accessdata.fda.gov/cdrh_docs/pdf16/P160002c.pdf. Accessed February 11, 2020.
United States Food and Drug Administration (FDA). Ventana PD-L1 (SP263) assay. 2017. Available at: www.accessdata.fda.gov/cdrh_docs/pdf16/p160046c.pdf. Accessed February 11, 2020.
Clinicaltrials.gov. A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer. 2019. Available at: www.clinicaltrials.gov/ct2/show/results/NCT02387996. Accessed June 27, 2019.
United States Food and Drug Administration (FDA). Approval package for: Application number: 125514Orig1s014; 2017. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125514Orig1s014.pdf. Accessed February 11, 2020.
Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753–3758.
Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16:30.
Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017:1–15.
Roupret M, Fromont G, Azzouzi AR, et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology. 2005;65:1233–1237.
Ju JY, Mills AM, Mahadevan MS, et al. Universal Lynch syndrome screening should be performed in all upper tract urothelial carcinomas. Am J Surg Pathol. 2018;42:1549–1555.
Adar T, Rodgers LH, Shannon KM, et al. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer. 2018;124:3145–3153.
Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79–86.
Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26:646–651.
Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301.
Beukers W, van der Keur KA, Kandimalla R, et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol. 2017;197:1410–1418.
Christensen E, Birkenkamp-Demtroder K, Nordentoft I, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71:961–969.
Kandimalla R, Masius R, Beukers W, et al. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin Cancer Res. 2013;19:4760–4769.
Zuiverloon TC, Beukers W, van der Keur KA, et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J Urol. 2013;189:1945–1951.
Sathianathen NJ, Butaney M, Weight CJ, et al. Urinary biomarkers in the evaluation of primary hematuria: a systematic review and meta-analysis. Bladder Cancer. 2018;4:353–363.
van Kessel KE, Beukers W, Lurkin I, et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urol. 2017;197:590–595.
van Kessel KE, Van Neste L, Lurkin I, et al. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol. 2016;195:601–607.
Khetrapal P, Lee MWL, Tan WS, et al. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: a systematic review. Cancer Treat Rev. 2018;66:56–63.
Krebs MG, Hou JM, Ward TH, et al. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351–365.
Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA. 2004;101:9393–9398.
Azevedo R, Soares J, Peixoto A, et al. Circulating tumor cells in bladder cancer: emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol. 2018;36:221–236.
Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547–1557.
United States Food and Drug Administration (FDA). EGFR mutation companion diagnostic. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019s019. Accessed February 11, 2020.
Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol. 2014;32:833–838.
Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24:517–523.
Al-Ahmadie HA, Iyer G, Lee BH, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48:356–358.
Fox MD, Xiao L, Zhang M, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases. Am J Clin Pathol. 2017;147:500–506.
Borhan WM, Cimino-Mathews AM, Montgomery EA, et al. Immunohistochemical differentiation of plasmacytoid urothelial carcinoma from secondary carcinoma involvement of the bladder. Am J Surg Pathol. 2017;41:1570–1575.
Goto K. CD138 expression is observed in the urothelial epithelium and in various urothelial carcinomas, and cannot be evidence for plasmacytoid urothelial carcinoma. Int J Surg Pathol. 2016;24:614–619.
Gaya JM, Palou J, Algaba F, et al. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol. 2010;17:5370–5376.
Kamat AM, Dinney CP, Gee JR, et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007;110:62–67.
Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175:881–885.
Isharwal S, Huang H, Nanjangud G, et al. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol. 2018;77:63–69.
Bertz S, Wach S, Taubert H, et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch. 2016;469:339–344.
Moktefi A, Pouessel D, Liu J, et al. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Mod Pathol. 2018;31:1270–1281.
Michaelson MD, Hu C, Pham HT, et al. A phase 1/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (Trial NRG Oncology RTOG 0524). Int J Radiat Oncol Biol Phys. 2017;97:995–1001.
Chang MT, Penson A, Desai NB, et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24:1965–1973.
Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103:1172–1178.
Lynch SP, Shen Y, Kamat A, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64:307–313.
Thompson S, Cioffi-Lavina M, Chapman-Fredricks J, et al. Distinction of high-grade neuroendocrine carcinoma/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: an immunohistochemical approach. Appl Immunohistochem Mol Morphol. 2011;19:395–399.
Wang G, Xiao L, Zhang M, et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018;79:57–65.
Rooper LM, Sharma R, Li QK, et al. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am J Surg Pathol. 2017;41:1561–1569.
Batista da Costa J, Gibb EA, Bivalacqua TJ, et al. Molecular characterization of neuroendocrine-like bladder cancer. Clin Cancer Res. 2019;25:3908–3920.
Veskimae E, Espinos EL, Bruins HM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol. 2019;2:625–642.